White House is excluding open-models from its framework to test advanced AI capabilities, according to Axios
Newsquawk Staff ·
White House is excluding open-models from its framework to test advanced AI capabilities, according to Axios.
What it means
Government testing and evaluation frameworks for frontier technology have historically served as soft gatekeeping: exclusion from such regimes tends to signal which development approaches regulators view as within the perimeter, and that signal often precedes harder policy. The distinction worth drawing is between closed and open-weight model developers, since the latter lack the controlled access and safety attestations that evaluators typically require, a fault line that has recurred in prior debates over dual-use technology controls. The actor set here is the administration rather than an independent agency, which in comparable episodes has meant the framework is policy direction rather than settled rule, and therefore subject to revision as agencies formalise it. The transmission channel for listed names runs through which labs and chip suppliers are deemed testable counterparties for government work, a categorisation that has in past episodes influenced procurement eligibility and, at the margin, investor grouping of AI-exposed equities. Worth watching is whether agencies convert the framework into formal procurement or export-control language and whether the excluded open-model camp lobbies for inclusion, since policy of this kind has tended to broaden rather than narrow over successive drafts. As a report rather than a published document, the read is directional pending the actual text.
- Iren (IREN) is to advance Europe's sovereign AI ambitions with 300mw Spanish campus
- CrowdStrike (CRWD) and Nvidia (NVDA) expand AI agent security to silicon; By 2028, production for Nvidia to account for significant portion of annual substrate capacity
- Oracle (ORCL) launches an AI agent studio for industry applications
- NVIDIA (NVDA) and Supply Chain Partners expand capacity to accelerate AI infrastructure buildout
- Daily US Equity Opening News - SPCX after results, TSLA talks; SMCI raises outlook; BA 737 MAX 10 receives FAA certification; UAL earnings/outlook miss; NFLX down on weak guidance
Related headlines
- Newsquawk Daily European Opening News - 21st October 20267 hours ago
- [EARNINGS CALL] SpaceX (SPCX) CEO Musk says demand for AI compute is likely to remain strong, with even older H100s (NVDA) renting for more than when they were new, while warning that a shortage of superintelligence compute could persist for a long time15 hours ago
- Super Micro Computer (SMCI) Q1 2027 Preliminary (USD): Net Sales 18.5bln-19.5bln (FactSet est. 14.99bln), Adj. Gross Margin 12%-12.5%. Revenue outlook above previous estimate of 14.5bln-15.5bln, driven by increased demand for AI platforms16 hours ago
- Amazon (AMZN) is buying billions in Nvidia (NVDA) AI systems it can't yet turn on, Business Insider reports18 hours ago
- US EQUITY OPEN: Indices weaker as Tech lags led by CRWV sell-off22 hours ago
- Hims (HIMS) expands testosterone care with injectable and oral TRT, its largest men’s health launch to date20 min ago
- Google (GOOGL) launches OpenAI models through its cloud31 min ago
- eBay (EBAY) reportedly cutting 9% of workforce to simplify operations and prioritise growth areas51 min ago
- NextEra Energy Inc. (NEE) Q3 2026 (USD): Adj. EPS 1.24 (exp. 1.18), Adj. net income 2.59bln (exp. 2.43bln)1 hour ago
- Abbott Laboratories (ABT) Q3 2026 (USD): Adj. EPS 1.42 (exp. 1.42), Revenue 13.0bln (exp. 12.99bln)1 hour ago
- Abbott (ABT) announced its intention to separate its Nutrition business into an independent, publicly traded company with approximately USD 8.5bln in annual sales and a portfolio of brands1 hour ago
- CME Group Inc. (CME) Q3 2026 (USD): Adj. EPS 3.02 (exp. 2.98), Revenue 1.7bln (exp. 1.71bln)1 hour ago
- Moody's (MCO) Q3 2026 (USD): Adj. EPS 4.14 (exp. 4.24), Revenue 2.023bln (exp. 2.07bln)1 hour ago
- Philip Morris International Inc. (PM) Q3 2026 (USD): Adj. EPS 2.36 (exp. 2.29), Net revenue 11.4bln (exp. 11.32bln)1 hour ago
- European Commision has improved Merck's (MRK) Keytruda plus Padcev, as perioperative treatment1 hour ago